More Trouble For Teva Pharmaceutical Industries Limited As U.S. Probes Marketing Of Drugs

Teva Pharmaceutical Industries Ltd said on Monday that the U.S. Department of Justice has opened an investigation into the marketing and promotion of multiple sclerosis drug Copaxone and Parkinson's Disease treatment Azilect. Copaxone is one of the Israeli drug company's top branded drugs, accounting for about 20 percent of sales and 50 percent of profit. In 2013, Copaxone sales were $4.3 billion and Azilect sales were $493 million. Teva is the world's largest maker of generic drugs but also manufactures some branded drugs as well.

Help employers find you! Check out all the jobs and post your resume.